EP3191096A4 - Dosage d'inhibiteur de la phosphatase chez un patient humain - Google Patents
Dosage d'inhibiteur de la phosphatase chez un patient humain Download PDFInfo
- Publication number
- EP3191096A4 EP3191096A4 EP15840637.1A EP15840637A EP3191096A4 EP 3191096 A4 EP3191096 A4 EP 3191096A4 EP 15840637 A EP15840637 A EP 15840637A EP 3191096 A4 EP3191096 A4 EP 3191096A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- phosphatase inhibitor
- human dosing
- dosing
- human
- phosphatase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940122907 Phosphatase inhibitor Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462049608P | 2014-09-12 | 2014-09-12 | |
US201562118265P | 2015-02-19 | 2015-02-19 | |
US201562209078P | 2015-08-24 | 2015-08-24 | |
PCT/US2015/049807 WO2016040877A1 (fr) | 2014-09-12 | 2015-09-11 | Dosage d'inhibiteur de la phosphatase chez un patient humain |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3191096A1 EP3191096A1 (fr) | 2017-07-19 |
EP3191096A4 true EP3191096A4 (fr) | 2018-03-21 |
Family
ID=55453712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15840637.1A Withdrawn EP3191096A4 (fr) | 2014-09-12 | 2015-09-11 | Dosage d'inhibiteur de la phosphatase chez un patient humain |
Country Status (6)
Country | Link |
---|---|
US (1) | US20160074390A1 (fr) |
EP (1) | EP3191096A4 (fr) |
CN (1) | CN107072991A (fr) |
AU (1) | AU2015314753A1 (fr) |
CA (1) | CA2960989A1 (fr) |
WO (1) | WO2016040877A1 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010147612A1 (fr) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Procédés de modulation de la régulation cellulaire par inhibition de p53 |
CA2876703A1 (fr) * | 2012-06-29 | 2014-01-03 | Lixte Biotechnology, Inc. | Oxabicycloheptanes et oxabicycloheptenes pour le traitement d'une lesion de reperfusion |
AU2013282365A1 (en) | 2012-06-29 | 2015-02-19 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes |
US10532050B2 (en) | 2013-04-09 | 2020-01-14 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
JP6453441B2 (ja) | 2014-07-24 | 2019-01-16 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ2a阻害剤 |
EP3258930B1 (fr) | 2015-02-19 | 2020-12-09 | Lixte Biotechnology, Inc. | Oxabicycloheptanes et oxabicycloheptènes permettant de traiter des troubles dépressifs et de stress |
EP3736275B1 (fr) | 2015-05-15 | 2024-07-03 | Lixte Biotechnology, Inc. | Promédicaments d'oxabicycloheptane pour leur utilisation dans le traitement du cancer |
US20190111053A1 (en) * | 2016-01-27 | 2019-04-18 | Lixte Biotechnology, Inc. | Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor |
KR20190098995A (ko) * | 2016-12-08 | 2019-08-23 | 릭스트 바이오테크놀로지, 인코포레이티드 | 면역 반응의 조절을 위한 옥사바이사이클로헵탄 |
CN109833327A (zh) * | 2017-11-28 | 2019-06-04 | 中国科学院大连化学物理研究所 | 一种增加化疗药物Gemcitabine对膀胱癌细胞的敏感性的药物组合物 |
CN109833475A (zh) * | 2017-11-28 | 2019-06-04 | 中国科学院大连化学物理研究所 | Pd-1 抑制剂与 pp2a 磷酸酶抑制剂在膀胱癌治疗药物中的应用 |
US20210275521A1 (en) * | 2017-12-05 | 2021-09-09 | Lixte Biotechnology, Inc. | Oxabicycloheptanes for treatment of secondary acute myeloid leukemia |
WO2019185708A1 (fr) | 2018-03-28 | 2019-10-03 | Georg-August-Universitaet Goettingen, Stiftung Oeffentlichen Rechts, Universitaetsmedizin | Prévention ou traitement d'une lésion d'organe chronique |
WO2019229757A1 (fr) * | 2018-05-31 | 2019-12-05 | Immunity Pharma Ltd. | Compositions et leurs méthodes d'utilisation pour le traitement de la sclérose latérale amyotrophique (sla) |
CN109602760B (zh) * | 2018-12-29 | 2021-03-30 | 江苏靶标生物医药研究所有限公司 | 一种铂类化合物和肝素类化合物的组合物及其应用 |
EP4171560A1 (fr) * | 2020-06-29 | 2023-05-03 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Nouvelle polythérapie pour le traitement d'une maladie du squelette liée à fgfr3 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8058268B2 (en) * | 2008-08-01 | 2011-11-15 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
WO2014005080A1 (fr) * | 2012-06-29 | 2014-01-03 | Lixte Biotechnology, Inc. | Oxabicycloheptanes et oxabicycloheptènes pour le traitement d'une lésion de reperfusion |
WO2014005084A1 (fr) * | 2012-06-29 | 2014-01-03 | Lixte Biotechnology, Inc. | Oxabicycloheptanes et oxabicycloheptènes pour le traitement du diabète |
WO2014168941A1 (fr) * | 2013-04-09 | 2014-10-16 | Lixte Biotechnology, Inc. | Formulations d'oxabicycloheptanes et d'oxabicycloheptènes |
WO2015196073A1 (fr) * | 2014-06-20 | 2015-12-23 | Lixte Biotechnology, Inc. | Oxabicycloheptanes et oxabicycloheptènes pour le traitement du cancer des ovaires |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2676422C (fr) * | 2007-02-06 | 2018-10-16 | Lixte Biotechnology Holdings, Inc. | Oxabicycloheptanes et oxabicylcoheptenes, leur preparation et utilisation |
-
2015
- 2015-09-11 AU AU2015314753A patent/AU2015314753A1/en not_active Abandoned
- 2015-09-11 CN CN201580057532.1A patent/CN107072991A/zh active Pending
- 2015-09-11 WO PCT/US2015/049807 patent/WO2016040877A1/fr active Application Filing
- 2015-09-11 EP EP15840637.1A patent/EP3191096A4/fr not_active Withdrawn
- 2015-09-11 US US14/852,219 patent/US20160074390A1/en not_active Abandoned
- 2015-09-11 CA CA2960989A patent/CA2960989A1/fr not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8058268B2 (en) * | 2008-08-01 | 2011-11-15 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
WO2014005080A1 (fr) * | 2012-06-29 | 2014-01-03 | Lixte Biotechnology, Inc. | Oxabicycloheptanes et oxabicycloheptènes pour le traitement d'une lésion de reperfusion |
WO2014005084A1 (fr) * | 2012-06-29 | 2014-01-03 | Lixte Biotechnology, Inc. | Oxabicycloheptanes et oxabicycloheptènes pour le traitement du diabète |
WO2014168941A1 (fr) * | 2013-04-09 | 2014-10-16 | Lixte Biotechnology, Inc. | Formulations d'oxabicycloheptanes et d'oxabicycloheptènes |
WO2015196073A1 (fr) * | 2014-06-20 | 2015-12-23 | Lixte Biotechnology, Inc. | Oxabicycloheptanes et oxabicycloheptènes pour le traitement du cancer des ovaires |
Non-Patent Citations (5)
Title |
---|
ANROOPB NAIR ET AL: "A simple practice guide for dose conversion between animals and human", JOURNAL OF BASIC AND CLINICAL PHARMACY, vol. 7, no. 2, 1 January 2016 (2016-01-01), India, pages 27, XP055407475, ISSN: 0976-0105, DOI: 10.4103/0976-0105.177703 * |
D. WEI ET AL: "Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair", CLINICAL CANCER RESEARCH, vol. 19, no. 16, 18 June 2013 (2013-06-18), US, pages 4422 - 4432, XP055450180, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-13-0788 * |
K.-E. CHANG ET AL: "The Protein Phosphatase 2A Inhibitor LB100 Sensitizes Ovarian Carcinoma Cells to Cisplatin-Mediated Cytotoxicity", MOLECULAR CANCER THERAPEUTICS, vol. 14, no. 1, 5 November 2014 (2014-11-05), US, pages 90 - 100, XP055435355, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-14-0496 * |
See also references of WO2016040877A1 * |
VINCENT M. CHUNG ET AL: "A phase 1 study of a novel inhibitor of protein phosphatase 2A alone and with docetaxel.", ASCO MEETING LIBRARY, 1 June 2014 (2014-06-01), pages 1 - 2, XP055450292, Retrieved from the Internet <URL:https://meetinglibrary.asco.org/record/98314/abstract> [retrieved on 20180212] * |
Also Published As
Publication number | Publication date |
---|---|
WO2016040877A1 (fr) | 2016-03-17 |
CA2960989A1 (fr) | 2016-03-17 |
CN107072991A (zh) | 2017-08-18 |
AU2015314753A1 (en) | 2017-04-06 |
US20160074390A1 (en) | 2016-03-17 |
EP3191096A1 (fr) | 2017-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1245247A1 (zh) | 溴結構域的抑制劑 | |
IL251584B (en) | Dihydropyrrolopyridines ror–gamma inhibitors | |
EP3191096A4 (fr) | Dosage d'inhibiteur de la phosphatase chez un patient humain | |
EP3102576B8 (fr) | Inhibiteurs de ror-gamma à base de dihydropyrrolopyridine | |
EP3127357B8 (fr) | Système de vie | |
EP3137169A4 (fr) | Inhibiteurs de la déméthylase-1 spécifiques de la lysine | |
EP3189038A4 (fr) | Inhibiteurs de la déméthylase 1 spécifique de la lysine | |
EP3140722A4 (fr) | Caractérisation d'états de sujet | |
EP3160956A4 (fr) | Inhibiteurs de la déméthylase-1 spécifique de la lysine | |
EP3164380A4 (fr) | Inhibiteurs de la déméthylase-1 spécifique de la lysine | |
EP3164509A4 (fr) | Inhibiteurs de la déméthylase 1 spécifique de la lysine | |
EP3143711A4 (fr) | Calcul de distances de dispositifs | |
EP3384921A4 (fr) | Nouvelle utilisation de la thiopeptine | |
EP3229813A4 (fr) | Traitement d'une l'inflammation médiée par hmgb1 | |
EP3119199A4 (fr) | Composés et procédés d'utilisation desdits composés | |
EP3193904A4 (fr) | Dipeptidomimetiques en tant qu'inhibiteurs des immunoproteasomes humains | |
HK1223624A1 (zh) | 替諾福韋的固體形式 | |
EP3338775A4 (fr) | Utilisation de butylidène-phthalide | |
EP3212202A4 (fr) | Utilisation d'agents thérapeutiques | |
AU2015903172A0 (en) | Inhibitors of necroptosis | |
AU2015900416A0 (en) | Inhibitors of necroptosis | |
AU2014904330A0 (en) | Use of therapeutic agents | |
GB201417646D0 (en) | Formulations of phosphate derivatives | |
AU2014904443A0 (en) | Management of Construction Projects | |
GB201418230D0 (en) | Construction of surfaces |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20170315 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20180220 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/496 20060101AFI20180214BHEP Ipc: A61P 3/10 20060101ALI20180214BHEP Ipc: A61K 31/704 20060101ALI20180214BHEP Ipc: A61K 31/495 20060101ALI20180214BHEP Ipc: A61K 45/06 20060101ALI20180214BHEP Ipc: A61K 33/24 20060101ALI20180214BHEP Ipc: A61K 31/4188 20060101ALI20180214BHEP Ipc: A61K 31/337 20060101ALI20180214BHEP Ipc: A61P 9/10 20060101ALI20180214BHEP Ipc: A61K 31/44 20060101ALI20180214BHEP Ipc: A61P 25/28 20060101ALI20180214BHEP Ipc: A61K 31/475 20060101ALI20180214BHEP Ipc: A61P 35/00 20060101ALI20180214BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1250568 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20181214 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20190425 |